Menlo Therapeutics’ Phase 2 Serlopitant Study for the Treatment of Chronic Pruritus Published in Journal

Pharmaceutical Investing

Menlo Therapeutics (NASDAQ:MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant, for the treatment of pruritus associated with various underlying dermatologic conditions and for refractory chronic cough, today announced that data assessing the safety and efficacy of serlopitant, the company’s NK-1 receptor antagonist, in treating chronic pruritus was published in the Journal of the …

Menlo Therapeutics (NASDAQ:MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant, for the treatment of pruritus associated with various underlying dermatologic conditions and for refractory chronic cough, today announced that data assessing the safety and efficacy of serlopitant, the company’s NK-1 receptor antagonist, in treating chronic pruritus was published in the Journal of the American Academy of Dermatology (JAAD).

As quoted in the press release:

The safety and efficacy results of this study were previously presented at the 26th European Academy of Dermatology and Venereology conference by Professor Dr. Sonja Ständer, Professor of Dermatology and Neurodermatology, head of the Center for Chronic Pruritus of the University Hospital Münster, Germany. Data on the early onset of effect of serlopitant in this study were presented at the same conference by Paul Kwon, MD, Chief Medical Officer of Menlo Therapeutics.

Click here to read the full press release.

The Conversation (0)
×